Market Overview

Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma

Share:

Aura
Biosciences
, a leader in the development of novel targeted therapies
in ocular oncology, today announced that Julie Feder has joined the
company's leadership team as Chief Financial Officer. In addition, the
company announced the addition of Kylie Reynolds as Vice President of
Finance, further augmenting Aura's in-house finance expertise as the
company finalizes its Phase 1/2 clinical trial and prepares to initiate
late stage clinical development for its flagship drug in choroidal
melanoma next year.

"We're excited to welcome Julie and Kylie to our team at this important
moment for our company," said Elisabet de los Pinos, Ph.D., founder and
CEO of Aura. "Their combined four-plus decades of experience in
financial management will be an asset in our accelerated progress
towards developing a groundbreaking new treatment for patients with
choroidal melanoma."

Ms. Feder joins Aura from Verastem, where she served as Chief Financial
Officer. At Verastem, Ms. Feder was responsible for developing the
company's strategic financial plan and overseeing a rapid growth in
financing and staff size. Prior to joining Verastem, Ms. Feder spent six
years at the Clinton Health Access Initiative, Inc. (CHAI) as Chief
Financial Officer. At CHAI, Ms. Feder was responsible for managing a
global team across multiple departments. She also developed the global
finance strategy and internal audit, treasury, and global payroll
functions. Ms. Feder holds a Bachelor of Science in Accounting from
Yeshiva University's Sy Syms School of Business.

Ms. Reynolds comes to Aura from Forma Therapeutics, where she served as
Senior Director and Controller for the company since 2015. In that role,
Ms. Reynolds was responsible for assessing systems, people and processes
to prepare the company for financial transformation. Ms. Reynolds holds
an M.S. in Banking and Financial Management from Boston University and
is a Certified Public Accountant.

About choroidal melanoma

Choroidal melanoma is a rare and aggressive type of eye cancer.
Choroidal melanoma is the most common primary ocular tumor and develops
in the uveal tract of the eye. No targeted therapies are available at
present, and current radiotherapy treatments can be associated with
severe visual loss and other long-term sequelae such as dry eye,
glaucoma, cataracts and radiation retinopathy. The most common current
treatment is plaque radiotherapy, which involves surgical placement of a
radiation device on the exterior of the eye over the tumor. The
alternative is enucleation, or total surgical removal of the eye.
Choroidal melanoma metastasizes to the liver in about 40-50 percent of
cases in the long term (source: OMF),
and only 15 percent of patients whose melanoma has metastasized survive
beyond five years after diagnosis (source: ACS).

About light-activated AU-011

AU-011 is a first-in-class targeted therapy in development for the
primary treatment of choroidal melanoma. The therapy consists of
proprietary viral-like particle conjugates (VPC) that are activated with
an ophthalmic laser. The VPCs bind selectively to unique receptors on
cancer cells in the eye and are derived from technology originally
pioneered by Dr. John Schiller of the Center for Cancer Research at the
National Cancer Institute (NCI), recipient of the 2017 Lasker-DeBakey
Award. Upon activation with an ophthalmic laser, the drug rapidly and
specifically disrupts the cell membrane of tumor cells while sparing key
eye structures, which may allow for the potential of preserving
patients' vision and reducing other long-term complications of radiation
treatment. AU-011 can be delivered using equipment commonly found in an
ophthalmologist's office and does not require a surgical procedure,
pointing to a potentially less invasive, more convenient therapy for
patients and physicians. AU-011 for the treatment of choroidal melanoma
has been granted orphan drug and fast track designations by the U.S.
Food and Drug Administration and is currently in clinical development.

About Aura Biosciences

Aura Biosciences is developing a new class of therapies to selectively
target and destroy cancer cells. Its lead program, AU-011 in primary
choroidal melanoma, is being developed under a CRADA with the National
Cancer Institute (NCI), part of the National Institutes of Health. For
more information, visit www.aurabiosciences.com.

View Comments and Join the Discussion!